We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
Read MoreHide Full Article
Shares of Monopar Therapeutics (MNPR - Free Report) , a clinical-stage biotech, skyrocketed 383.5% in the past three months fueled by a licensing agreement with AstraZeneca (AZN - Free Report) , which granted MNPR an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate). ALXN-1840 is an investigational once-daily, oral medicine, which is being developed for treating Wilson disease, a rare and progressive genetic disease.
AstraZeneca had earlier announced that a pivotal phase III study evaluating the candidate for the above indication had met its primary endpoint. Although AZN terminated the ALXN-1840 program in 2023, Monopar took up the candidate upon the request of the Wilson Disease Association. AstraZeneca’s termination of the ALXN-1840 program was based on the review of results from phase II mechanistic studies and discussions with regulatory authorities.
In the past six months, shares of Monopar have rallied 525.5% against the industry’s 4.8% decline.
Image Source: Zacks Investment Research
More on the Licensing Deal Between MNPR and AZN
The licensing agreement with AstraZeneca added a late-stage candidate to Monopar’s early-stage pipeline. This has brought MNPR significantly close to becoming a commercial-stage company.
Following the deal, Monopar has assumed responsibilities for all future global development and commercialization activities related to ALXN-1840 to treat Wilson disease. Management believes that the company’s expertise in rare disease drug development and commercialization will catapult ALXN-1840 into a successful product for the above indication.
Under the terms of the transaction, Monopar is liable to make an undisclosed upfront cash payment to AstraZeneca, along with a stake in its equity, in consideration of the global rights to ALXN-1840. The company shall also be liable to make additional payments to AZN based on the achievement of certain pre-determined regulatory and sales milestones. AstraZeneca is also eligible to receive tiered royalties on net sales from Monopar if ALXN-1840 is approved and launched.
Per MNPR, ALXN-1840 has significant market opportunity as one in 30,000 live births in the United States are affected by Wilson disease.
Monopar will initially be focusing on developing ALXN-1840 for patients with more severe Wilson disease symptoms. It is gearing up to hold discussions with the FDA to figure out a path forward for the candidate.
Apart from ALXN-1840, the company is currently evaluating several other candidates for various oncology indications in separate early-stage studies.
In the past 60 days, 2024 estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In the past three months, shares of Castle Biosciences have lost 6.2%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past three months, Spero’s shares have lost 20.2%.
SPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
Shares of Monopar Therapeutics (MNPR - Free Report) , a clinical-stage biotech, skyrocketed 383.5% in the past three months fueled by a licensing agreement with AstraZeneca (AZN - Free Report) , which granted MNPR an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate). ALXN-1840 is an investigational once-daily, oral medicine, which is being developed for treating Wilson disease, a rare and progressive genetic disease.
AstraZeneca had earlier announced that a pivotal phase III study evaluating the candidate for the above indication had met its primary endpoint. Although AZN terminated the ALXN-1840 program in 2023, Monopar took up the candidate upon the request of the Wilson Disease Association. AstraZeneca’s termination of the ALXN-1840 program was based on the review of results from phase II mechanistic studies and discussions with regulatory authorities.
In the past six months, shares of Monopar have rallied 525.5% against the industry’s 4.8% decline.
Image Source: Zacks Investment Research
More on the Licensing Deal Between MNPR and AZN
The licensing agreement with AstraZeneca added a late-stage candidate to Monopar’s early-stage pipeline. This has brought MNPR significantly close to becoming a commercial-stage company.
Following the deal, Monopar has assumed responsibilities for all future global development and commercialization activities related to ALXN-1840 to treat Wilson disease. Management believes that the company’s expertise in rare disease drug development and commercialization will catapult ALXN-1840 into a successful product for the above indication.
Under the terms of the transaction, Monopar is liable to make an undisclosed upfront cash payment to AstraZeneca, along with a stake in its equity, in consideration of the global rights to ALXN-1840. The company shall also be liable to make additional payments to AZN based on the achievement of certain pre-determined regulatory and sales milestones. AstraZeneca is also eligible to receive tiered royalties on net sales from Monopar if ALXN-1840 is approved and launched.
Per MNPR, ALXN-1840 has significant market opportunity as one in 30,000 live births in the United States are affected by Wilson disease.
Monopar will initially be focusing on developing ALXN-1840 for patients with more severe Wilson disease symptoms. It is gearing up to hold discussions with the FDA to figure out a path forward for the candidate.
Apart from ALXN-1840, the company is currently evaluating several other candidates for various oncology indications in separate early-stage studies.
Monopar Therapeutics Inc. Price and Consensus
Monopar Therapeutics Inc. price-consensus-chart | Monopar Therapeutics Inc. Quote
MNPR’s Zacks Rank & Other Stocks to Consider
Monopar currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks from the sector are Castle Biosciences (CSTL - Free Report) and Spero Therapeutics (SPRO - Free Report) , each presently sporting a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, 2024 estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In the past three months, shares of Castle Biosciences have lost 6.2%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past three months, Spero’s shares have lost 20.2%.
SPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.